13th Edition of International Conference on Neurology and Brain Disorders
October 19-21, 2026
Neuromodulation
Neuromodulation orchestrates the delicate dance of neural activity within the intricate tapestry of the nervous system. Unlike the rapid synaptic transmission mediated by neurotransmitters, neuromodulators operate on longer timescales, exerting influence over multiple neurons simultaneously. They regulate neuronal activity across various levels of the nervous system, from individual synapses to entire brain regions. These modulators encompass both endogenous substances, such as dopamine and serotonin, which naturally regulate neural function, and exogenous agents, like electrical stimulation or pharmacological compounds, introduced to alter neural activity. Neuromodulation's effects span from modifying neuronal excitability to shaping synaptic plasticity, the foundation of learning and memory. In the realm of basic neuroscience research, neuromodulation techniques unravel the complexities of neuronal circuits, shedding light on how these circuits sculpt behavior and cognition. Clinically, neuromodulation therapies offer promising avenues for treating neurological and psychiatric disorders, from chronic pain to depression, leveraging approaches like deep brain stimulation and transcranial magnetic stimulation to restore neural balance.
Ken Ware
NeuroPhysics Therapy Institute and Research Centre, Australia
Yong Xiao Wang
Albany Medical College, United States
Joe Sam Robinson
Mercer University, United States
Daniel Curry
Texas Children’s Hospital, United States
Steven Benvenisti
Davis, Saperstein Salomon, PC, United States
Andrzej Stanislaw Cieplak
Independent researcher, United States
Younok Dumortier Shin
OnusBio, United StatesSubmit your abstract Today
Title : Atypical presentation of Juvenile myoclonic epilepsy in a 16-year-old female: A case report
George Diaz, Memorial Healthcare Systems, United States
Title : Triple-network dysfunction, ME/CFS, and the NeuroPhysics Treatment Process “A dynamical systems perspective on psychophysical organization and environmental interaction”
Ken Ware, NeuroPhysics Therapy Institute and Research Centre, Australia
Title : Beyond plaques: 10-nanometer-scale pathoconnectomics of Alzheimer’s disease
Ons M Saad, Panluminate Inc., United States
Title : Results from the global phase 3 trial (IB1001-303) evaluating levacetylleucine in children and adults with ataxia-telangiectasia
Chidinma Ejim, IntraBio, United States
Title : A phase 3, multinational, randomized, placebo-controlled, double-blind, crossover trial (IB1001-304) evaluating levacetylleucine in CACNA1A
Chidinma Ejim, IntraBio, United States
Title : Clinical and molecular phenotype of PTRHD1-associated juvenile parkinsonism
Bhavan A Modi, Barrow Neurological Institute at Phoenix Children's, United States